With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, ...

Moderna Inc.’s stock reached a 52-week low, closing at 23.04 USD, reflecting a significant downturn over the past year. The biotech company’s shares have experienced a substantial decline, with a year ...

At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into ...

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...

US biotech Moderna has held an analyst day event providing updates on its mRNA pipeline progress and a three-year plan for strategic growth.

Design Therapeutics (DSGN) stock gains as RBC upgrades the biotech, citing a catalyst-rich near-term outlook for the company. Read more here.

US pharma giant Pfizer has provided a reminder of the merits of mRNA-based vaccines as health leaders in the USA continue to question their safety.

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Moderna (NASDAQ:MRNA) gained 3% on Thursday after presenting a new multi-year roadmap at its Analyst Day, detailing how it ...

Conformity with stringent new EU regulations for medical devices confirmedAllows for commercialization of Bentrio in EU ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.